Shokji, S. and M. Esashi, “Microflow Devices and Systems,” J. Micromech. Microeng., 4: 157-71 (1994).* |
Santini, Jr., J.T., M. J. Cima, and R. Langer, “A Controlled-Release Microchip,” Nature, 397: 335-38 (1999).* |
Santini, Jr., J.T., A.C. Richards, R. Scheidt, M. J. Cima, and R. Langer, “Microchips as Controlled Drug-Delivery Devices,” Angew. Chem. Int. Ed. 39: 2396-407 (2000).* |
Badesch, D.E.A., Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. Ann. Intern. Med., 2000. 132(6): p. 425-434. |
Hooper, M.M., M.D., et al., A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. American College of Cardiology, 2000. 35(1): p. 176-182. |
Ensor, C.M., et al., Cloning and sequence analysis of the cDNA for human placental NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase. J. Biol. Chem., 1990. 265(25): p. 14888-91. |
Ensor, C.M. and H.H. Tai, Bacterial expression and site-directed mutagenesis of two critical residues (tyrosine-151 and lysine-155) of human placental NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase. Biochim. Biophys. Acta, 1994. 1208(1): p. 151-6. |
Ensor, C.M., H. Zhang, and H.H. Tai, Purification, cDNA cloning and expression of 15-oxoprostaglandin 13-reductase from pig lung. Biochem. J., 1998. 330(Pt 1): p. 103-8. |
Drug delivery showing strength in wake of drug efficacy efforts. Chemical Market Reporter, 1997. 252 (Sep. ): p. 10. |
Drug delivery system: polymers expected to dominate world market by 1996. Gazeta Mercantil. |
Wilson, G. and Y. Hu, Enzyme-based biosensors for in vivo measurements. Chem. Rev., 2000. 100(7): p. 2693-2704. |
Madou, M.J. and M. Tierney. 1994: Micro-electrochemical valves and methods, United States Patent, 5,368,704. |
Glaxo Wellcome, I., www.glaxowellcome.com. |
Wilson, G. and Y. Hu, Enzyme-based biosensors for in vivo measurements. Chem. Rev., 2000. 100(7): p. 2693-2704. |
Bowyer, J.R., et al., Energy Res. Abstr., 1991: p. 30. |
Xie, S.L., E. Wilkins, and P. Atanasov, Sens. Actuators, 1994. 17(2): p. 133-42. |
Madou, M.J. and M. Tierney. 1994: Micro-electrochemical valves and methods, United States Patent, 5,368,704. |
Glaxo Wellcome, I., www.glaxowellcome.com. |
United Therapeutics Corporation S-1 filing. Securities and Exchange Commission: EDGAR, 1999 (Apr.). |
Badesch, D.E.A., Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. Ann. Intern. Med., 2000. 132(6): p.425-434. |
Dollery, C.T., Ther. Drugs. 1998. |
Hooper, M.M., M.D., et al., A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. American College of Cardiology, 2000. 35(1): p. 176-182. |
Ensor, C.M., et al., Cloning and sequence analysis of the cDNA for human placental NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase. J. Biol. Chem., 1990. 265(25): p. 14888-91. |
Ensor, C.M. and H.H. Tai, Bacterial expression and site-directed mutagenesis of two critical residues (tyrosine-151 and lysine-155) of human placental NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase. Biochim. Biophys. Acta, 1994. 1208(1): p. 151-6. |
Ensor, C.M., H. Zhang, and H.H. Tai, Purification, cDNA cloning and expression of 15-oxoprostaglandin 13-reductase from pig lung. Biochem. J., 1998. 330(Pt 1): p. 103-8. |
Drug delivery showing strength in wake of drug efficacy efforts. Chemical Market Reporter, 1997. 252 (Sep. ): p. 10. |
Drug delivery deveopment proliferation. Medical & Healthcare Marketplace Guide, 1997 (Jan.). |
Drug delivery market faces increased consolidation. Chemical Market Reporter, 1998 (Nov.). |
Drug delivery systems: polymers expected dominate world market by 1996. Gazeta Mercantil. |
Drug delivery changing times. Med. Ad. News, 1999. 18 (Aug.): p. 8. |